Bifidobacterium infantis 35624

B. infantis 35624 promoted immuno-regulatory responses in healthy subjects, enhancing tolerance in the gastrointestinal mucosa and suggesting potential for reducing inflammation systemically.

Oral administration of B. infantis 35624 for 6-8 weeks reduced plasma CRP, TNF-α, and IL-6 levels in patients with ulcerative colitis, chronic fatigue syndrome, and psoriasis, normalizing cytokine profiles to levels seen in healthy volunteers. The strain demonstrated systemic anti-inflammatory effects.

In 58 children and adolescents with IBS, 12 weeks of 1x10^9 CFU daily significantly decreased abdominal pain frequency and severity, distension, and life impact, while improving bowel habit satisfaction, independent of vitamin D status. The probiotic was well-tolerated with no adverse effects noted.

In women with IBS, 1x10^8 CFU of B. infantis 35624 significantly reduced abdominal pain, bloating, bowel dysfunction, and gas compared to placebo after 4 weeks, with global symptom improvement exceeding placebo by over 20%. No significant adverse events were reported.

B. infantis 35624 promoted immuno-regulatory responses in healthy subjects, enhancing tolerance in the gastrointestinal mucosa and suggesting potential for reducing inflammation systemically.

Oral administration of B. infantis 35624 for 6-8 weeks reduced plasma CRP, TNF-α, and IL-6 levels in patients with ulcerative colitis, chronic fatigue syndrome, and psoriasis, normalizing cytokine profiles to levels seen in healthy volunteers. The strain demonstrated systemic anti-inflammatory effects.

In 58 children and adolescents with IBS, 12 weeks of 1x10^9 CFU daily significantly decreased abdominal pain frequency and severity, distension, and life impact, while improving bowel habit satisfaction, independent of vitamin D status. The probiotic was well-tolerated with no adverse effects noted.

In women with IBS, 1x10^8 CFU of B. infantis 35624 significantly reduced abdominal pain, bloating, bowel dysfunction, and gas compared to placebo after 4 weeks, with global symptom improvement exceeding placebo by over 20%. No significant adverse events were reported.

In 58 children and adolescents with IBS, 12 weeks of 1x10^9 CFU daily significantly decreased abdominal pain frequency and severity, distension, and life impact, while improving bowel habit satisfaction, independent of vitamin D status. The probiotic was well-tolerated with no adverse effects noted.

In women with IBS, 1x10^8 CFU of B. infantis 35624 significantly reduced abdominal pain, bloating, bowel dysfunction, and gas compared to placebo after 4 weeks, with global symptom improvement exceeding placebo by over 20%. No significant adverse events were reported.